Combined Role of Interleukin-15 Stimulated Natural Killer Cell-Derived Extracellular Vesicles and Carboplatin in Osimertinib-Resistant H1975 Lung Cancer Cells with EGFR Mutations

Combined Role of Interleukin-15 Stimulated Natural Killer Cell-Derived Extracellular Vesicles and Carboplatin in Osimertinib-Resistant H1975 Lung Cancer Cells with EGFR Mutations

In this study, we evaluated IL-15 stimulated natural killer cell-derived EVs (NK-EVs) as therapeutic agents in vitro and in vivo in Osimertinib-resistant lung cancer (H1975R) with EGFR mutations (L858R) in combination with carboplatin (CBP). NK-EVs were isolated by ultracentrifugation and characteri...

Full description

Bibliographic Details
Main Authors:	Aakash Nathani, Li Sun, Islauddin Khan, Mounika Aare, Arvind Bagde, Yan Li, Mandip Singh
Format:	Article
Language:	English
Published:	MDPI AG 2024-01-01
Series:	Pharmaceutics
Subjects:	natural killer cells extracellular vesicles PD-L1 carboplatin Osimertinib resistance lung cancer
Online Access:	https://www.mdpi.com/1999-4923/16/1/83

Similar Items

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022-01-01)

PD‐L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR‐mutant non‐small cell lung cancer cells
by: Dantong Sun, et al.
Published: (2022-12-01)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
by: Mei-Mei Zheng, et al.
Published: (2022-05-01)

Response to Osimertinib in a Patient with Non-Small Cell Lung Cancer and Two Uncommon EGFR Mutations
by: Christoforos Astaras, et al.
Published: (2020-03-01)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
by: Hongjing Zang, et al.
Published: (2020-04-01)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
by: Fionnuala Crowley, MB BCh BAO, et al.
Published: (2022-01-01)

THE DIFFERENCES OF APOPTOSIS EFFECTS BETWEEN COMBINATION OF MELOXICAM WITH GEMCITABINE-CARBOPLATIN CHEMOTHERAPY COMPARED TO GEMCITABINE-CARBOPLATIN CHEMOTHERAPY ALONE IN UROTHELIAL CARCINOMA CULTURE CELLS
by: Ananta Cahyo Nugroho, et al.
Published: (2019-01-01)

COMPARISON BETWEEN GEMCITABINE-CARBOPLATIN AND COMBINATION OF GEMCITABINE-CARBOPLATIN AND CELECOXIB IN UROTHELIAL CARCINOMA CELL APOPTOSIS
by: Widya Sakti Pratama, et al.
Published: (2019-01-01)

Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib, CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment in NSCLC Tumor Xenografts
by: Ramesh Nimma, et al.
Published: (2022-05-01)

A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
by: Chul Kim, et al.
Published: (2021-09-01)

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer
by: Shaocong Wu, et al.
Published: (2021-01-01)

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
by: Kai Fu, et al.
Published: (2022-12-01)

Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions
by: Mengyao Sun, et al.
Published: (2022-02-01)

Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma
by: Chul Kim, et al.
Published: (2021-07-01)

Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
by: Galatea Kallergi, et al.
Published: (2022-03-01)

Osimertinib Re-challenge for EGFR-mutant NSCLC after  Osimertinib-induced Interstitial Lung Disease: A Case Report
by: Junjie GU, et al.
Published: (2021-11-01)

Osimertinib for the first-line treatment of EGFR-positive non-small cell lung cancer
by: Elena V Reutova, et al.
Published: (2019-09-01)

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
by: Yufeng Li, et al.
Published: (2023-04-01)

UBL3 Interacts with Alpha-Synuclein in Cells and the Interaction Is Downregulated by the EGFR Pathway Inhibitor Osimertinib
by: Bin Chen, et al.
Published: (2023-06-01)

Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib
by: Carolien Eggermont, et al.
Published: (2023-05-01)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
by: A.J. Piper-Vallillo, MD, et al.
Published: (2022-06-01)

Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment
by: Leydis Luna Torres, et al.
Published: (2021-10-01)

Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
by: Elisa Bertoli, et al.
Published: (2022-06-01)

Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer
by: Yingying Jiang, et al.
Published: (2022-06-01)

Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells
by: Xiao-Yu Zhang, et al.
Published: (2016-09-01)

Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
by: Judith L. Gulikers, MSc, et al.
Published: (2024-04-01)

Adenovirus pneumonia mimicking osimertinib‐induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report
by: Toru Imai, et al.
Published: (2024-03-01)

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
by: M. Jebbink, MD, et al.
Published: (2023-04-01)

Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report
by: Hongming Wang, et al.
Published: (2023-03-01)

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
by: Laksmi Wulandari, et al.
Published: (2022-01-01)

Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
by: Jie Wang, MD, PhD, et al.
Published: (2024-02-01)

Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion
by: Ayu Kiritani, et al.
Published: (2024-02-01)

A case report: Response to Osimertinib in non-small cell lung cancer patient with uncommon EGFR mutation
by: Daniel J. Craig, et al.
Published: (2022-12-01)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
by: Soei Gen, et al.
Published: (2022-06-01)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
by: Zentaro Saito, et al.
Published: (2023-10-01)

Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib
by: Wang L, et al.
Published: (2023-10-01)

Prognostic Significance of Pretreatment Plasma D-dimer Levels in EGFR-Positive Advanced Non-Small Cell Lung Cancer Patients Receiving Osimertinib: A Multicentre Retrospective Study
by: Liu Q, et al.
Published: (2023-11-01)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
by: Yu Wang, et al.
Published: (2021-10-01)

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
by: Lei Wen, et al.
Published: (2023-08-01)